Cargando…
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice
Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has recently been approved in several countries for use in advanced or metastatic non-small-cell lung cancer (NSCLC). In contrast to chemotherapies, which are generally used at or near their maximum-tolerate...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750242/ https://www.ncbi.nlm.nih.gov/pubmed/14661047 http://dx.doi.org/10.1038/sj.bjc.6601477 |